BRAF mutations increase response to MEK inhibition
Document Type
Article
Department
Ophthalmology
Abstract
Tumours with BRAF mutations, irrespective of site of origin, are sensitive to mitogen-activated protein kinase kinase (MEK) inhibitors, say researchers in Nature
Publication (Name of Journal)
Lancet Oncology
Recommended Citation
Ahmed, K.
(2005). BRAF mutations increase response to MEK inhibition. Lancet Oncology, 6(12), 926.
Available at:
https://ecommons.aku.edu/pakistan_fhs_mc_surg_surg/418
COinS